论文部分内容阅读
目的探讨术前放化疗对中晚期进展期直肠癌保肛手术的临床价值。方法选取郑州人民医院72例直肠癌患者,随机将患者平均分成两组,观察组患者给予术前新辅助放、化疗,对照组患者同期直接手术。随访分析两组患者保肛率及3a生存率。结果近期疗效上,观察组总有效率明显优于对照组(P<0.05);远期疗效上,两组3a生存率及术中淋巴结阳性率之间差别均有统计学意义(P<0.05);两组保肛率差异也有统计学意义(P<0.05)。结论术前加用放化疗在提高直肠癌患者保肛率的同时,可以提高患者3a生存率和降低淋巴结转移率,减少手术并发症和局部复发率。但其最终结果和远期疗效有待进一步观察和分析。
Objective To investigate the clinical value of preoperative chemoradiotherapy for anorectal surgery in advanced advanced rectal cancer. Methods Totally 72 patients with rectal cancer in Zhengzhou People’s Hospital were randomly divided into two groups. The patients in the observation group were given neoadjuvant radiotherapy, chemotherapy, and the control group received direct surgery at the same period. Follow-up analysis of two groups of patients anal retention rate and 3a survival rate. Results The total effective rate in the observation group was significantly better than that in the control group in the short term (P <0.05). There was a significant difference in the survival rate between the two groups in 3a and the positive rate of lymph node in the long term (P <0.05) There was also a significant difference in anal sphincter between the two groups (P <0.05). Conclusions Preoperative chemoradiotherapy combined with radiotherapy and chemotherapy can improve the survival rate of patients with 3a and reduce the rate of lymph node metastasis and reduce the incidence of surgical complications and local recurrence. However, its final outcome and long-term efficacy need to be further observed and analyzed.